MYOS RENS Technology, Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle in humans and canines, announced today that it has signed a distribution agreement with UNFI (United Natural Foods Inc.), a nationwide distributor with a comprehensive product portfolio of diverse, healthy and sustainable foods.
Today's 5 Stock Ideas: * Facebook (FB) \- An earnings play. The company will report quarterly results after the close Wednesday. * IBM (IBM) \- A dividend play. In an environment where the majority of publicly-traded companies are suspending dividend payments, IBM announced Tuesday afternoon it raised its quarterly dividend from $1.62 to $1.63/share. * Shopify (SHOP) \- A merchant/ecommerce play. Despite news Tuesday FedEx (FDX) will be partnering with Shopify competitor BigCommerce, shares of Shopify closed Tuesday's session up about 1%. * Monster Beverage (MNST) \- A play on an emerging competitor in the energy/nutritional drink space. Pepsi (PEP) Tuesday announced a partnership with Monster competitor, Bang Energy. While Monster shares fell as much as 3% at one point during Tuesday's session, the stock closed down just 0.6%. * MYOS RENS (MYOS) \- A play on animal health. The company reported Tuesday its MYOS Canine Muscle Formula is now eligible for reimbursement by several top-tier pet insurance companies.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 16, 2020: SPY, AAL, ZM, LVS, FDX(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
In April 2020, a 100-Dog Veterinary Study Showing Fortetropin®'s Impact on Dogs Recovering from TPLO Surgery, was Published in the Peer-Reviewed Journal, PLOS ONE CEDAR KNOLLS, N.J., May 8, 2020 /PRNewswire/ -- Company Conference Call: Today, May 8, 2020, at …
MYOS RENS Technology, Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, issued this shareholder letter highlighting its 2019 achievements and the Company's strategy going forward.
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced the publication of a study that concluded that the use of Fortetropin decreased muscle atrophy in dogs following tibial-plateau leveling osteotomy (TPLO).
CEDAR KNOLLS, N.J., April 28, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced today that…
Company Conference Call: Today, May 8, 2020, at 11:30 AM ET
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that it has hired former Rutgers University football player Eric LeGrand as a Special Advisor for its Yolked® sports nutrition brand.
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that it has entered into a distribution agreement with BodyLogicMD, a leading physician-owned network of anti-aging medical practices located throughout the United States.
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announces its results for the fiscal year ended December 31, 2019.
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that it has entered into a distribution agreement with Chewy (www.chewy.com), a leading online retailer of pet food and pet-related products. Chewy will distribute MYOS Canine Muscle Formula®, an advanced nutrition product that has been clinically shown to increase muscle mass, prevent atrophy of disuse and improve recovery from injuries in canines. This study was conducted at Kansas State University involving 100 dogs.
MYOS RENS Technology Inc. ("MYOS") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced today that it has entered into an agreement with Victor Medical Company ("VMC") to distribute its Veterinarian Strength MYOS Canine Muscle Formula® ("MYOS Canine") nutrition products through VMC's extensive distribution network across the Western United States.
CEDAR KNOLLS, N.J., May 14, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced today that it has entered int…
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that it has entered into an agreement with KVP International, Inc. ("KVP") (www.kvpvet.com), a leading supplier of innovative products for the veterinary rehabilitation market such as surgical supplies, recovery collars and braces.
Q4 2019 MYOS RENS Technology Inc Earnings Call
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that it will provide updates on its clinical research including its clinically-backed nutrition product, MYOS Canine Muscle Formula®, at the North American Veterinary Meeting & Expo (VMX) (https://navc.com/vmx/), Booth 2028, January 19-22, 2020 in Orlando, Florida.
In April 2020, a 100-Dog Veterinary Study Showing Fortetropin®'s Impact on Dogs Recovering from TPLO Surgery, was Published in the Peer-Reviewed Journal, PLOS ONE CEDAR KNOLLS, N.J., May 8, 2020 /PRNewswire/ -- Company Conference Call: Today, May 8, 2020, at …
Company Conference Call: Today, May 8, 2020, at 11:30 AM ET
“Outsourcing Specialist” and Oil Company Among Latest SBA PPP Recipients Q1 2020 hedge fund letters, conferences and more WASHINGTON, D.C. – The latest Securities and... The post Sypris Solutions and Amplify Energy Among Latest PPP Recipients appeared first o…
If you own shares in MYOS RENS Technology Inc. (NASDAQ:MYOS) then it's worth thinking about how it contributes to the...
Q1 2020 MYOS RENS Technology Inc Earnings Call
NEW YORK, NY / ACCESSWIRE / March 25, 2020 / MYOS RENS Technology, Inc. (NASDAQ:MYOS) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 25, 2020 at ...
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, will announce financial results for the fourth quarter of 2019 on Wednesday, March 25 at 11 AM (ET).
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, will announce financial results for the first quarter of 2020 on Friday, May 8, 2020 at 11:30 AM ET.
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced today that it has partnered with GetHealthy.store ("GetHealthy"), a Texas-based e-commerce platform serving a network of over 1,000 anti-aging practitioners nationwide. MYOS believes that this platform will greatly increase the level of awareness, education of, and encourage the adoption of, MYOS' products among medical practitioners and their patients.
High borrowing fees are a red flag for a stock. I compiled a list of stocks that have 50%+ fees to borrow (for shorting). Canadian cannabis and corona-related s
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced today that its MYOS Canine Muscle Formula® ("MYOS Canine") Regular and Veterinarian Strength, is now eligible for reimbursement by several top-tier pet insurance companies.
CEDAR KNOLLS, N.J., May 14, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced today that it has entered int…
CEDAR KNOLLS, N.J., May 21, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced today that i…
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced today that it has partnered with GetHealthy.store ("GetHealth…
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced today that its MYOS Canine Muscle Formula® ("MYOS Canine") Re…
MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, will announce financial results for the first quarter of 2020 on…